Can urinary PCA3 Supplement PSA in the early detection of prostate cancer?

John T. Wei, Ziding Feng, Alan W. Partin, Elissa Brown, Ian Thompson, Lori Sokoll, Daniel W. Chan, Yair Lotan, Adam S. Kibel, J. Erik Busby, Mohamed Bidair, Daniel W. Lin, Samir S. Taneja, Rosalia Viterbo, Aron Y. Joon, Jackie Dahlgren, Jacob Kagan, Sudhir Srivastava, Martin G. Sanda

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Purpose: Given the limited sensitivity and specificity of prostate-specific antigen (PSA), its widespread use as a screening tool has raised concerns for the overdiagnosis of low-risk and the underdiagnosis of high-grade prostate cancer. To improve early-detection biopsy decisions, the National Cancer Institute conducted a prospective validation trial to assess the diagnostic performance of the prostate cancer antigen 3 (PCA3) urinary assay for the detection of prostate cancer among men screened with PSA. Patients and Methods: In all, 859 men (mean age, 62 years) from 11 centers scheduled for a diagnostic prostate biopsy between December 2009 and June 2011 were enrolled. The primary outcomes were to assess whether PCA3 could improve the positive predictive value (PPV) for an initial biopsy (at a score >60) and the negative predictive value (NPV) for a repeat biopsy (at a score <20). Results: For the detection of any cancer, PPV was 80% (95% CI, 72% to 86%) in the initial biopsy group, and NPV was 88% (95% CI, 81% to 93%) in the repeat biopsy group. The addition of PCA3 to individual risk estimation models (which included age, race/ethnicity, prior biopsy, PSA, and digital rectal examination) improved the stratification of cancer and of high-grade cancer. Conclusion: These data independently support the role of PCA3 in reducing the burden of prostate biopsies among men undergoing a repeat prostate biopsy. For biopsy-naive patients, a high PCA3 score (>60) significantly increases the probability that an initial prostate biopsy will identify cancer.

Original languageEnglish (US)
Pages (from-to)4066-4072
Number of pages7
JournalJournal of Clinical Oncology
Volume32
Issue number36
DOIs
StatePublished - Dec 20 2014

Fingerprint

Prostate-Specific Antigen
Early Detection of Cancer
Prostatic Neoplasms
Biopsy
Antigens
Prostate
National Cancer Institute (U.S.)
Sensitivity and Specificity
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wei, J. T., Feng, Z., Partin, A. W., Brown, E., Thompson, I., Sokoll, L., ... Sanda, M. G. (2014). Can urinary PCA3 Supplement PSA in the early detection of prostate cancer? Journal of Clinical Oncology, 32(36), 4066-4072. https://doi.org/10.1200/JCO.2013.52.8505

Can urinary PCA3 Supplement PSA in the early detection of prostate cancer? / Wei, John T.; Feng, Ziding; Partin, Alan W.; Brown, Elissa; Thompson, Ian; Sokoll, Lori; Chan, Daniel W.; Lotan, Yair; Kibel, Adam S.; Busby, J. Erik; Bidair, Mohamed; Lin, Daniel W.; Taneja, Samir S.; Viterbo, Rosalia; Joon, Aron Y.; Dahlgren, Jackie; Kagan, Jacob; Srivastava, Sudhir; Sanda, Martin G.

In: Journal of Clinical Oncology, Vol. 32, No. 36, 20.12.2014, p. 4066-4072.

Research output: Contribution to journalArticle

Wei, JT, Feng, Z, Partin, AW, Brown, E, Thompson, I, Sokoll, L, Chan, DW, Lotan, Y, Kibel, AS, Busby, JE, Bidair, M, Lin, DW, Taneja, SS, Viterbo, R, Joon, AY, Dahlgren, J, Kagan, J, Srivastava, S & Sanda, MG 2014, 'Can urinary PCA3 Supplement PSA in the early detection of prostate cancer?', Journal of Clinical Oncology, vol. 32, no. 36, pp. 4066-4072. https://doi.org/10.1200/JCO.2013.52.8505
Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L et al. Can urinary PCA3 Supplement PSA in the early detection of prostate cancer? Journal of Clinical Oncology. 2014 Dec 20;32(36):4066-4072. https://doi.org/10.1200/JCO.2013.52.8505
Wei, John T. ; Feng, Ziding ; Partin, Alan W. ; Brown, Elissa ; Thompson, Ian ; Sokoll, Lori ; Chan, Daniel W. ; Lotan, Yair ; Kibel, Adam S. ; Busby, J. Erik ; Bidair, Mohamed ; Lin, Daniel W. ; Taneja, Samir S. ; Viterbo, Rosalia ; Joon, Aron Y. ; Dahlgren, Jackie ; Kagan, Jacob ; Srivastava, Sudhir ; Sanda, Martin G. / Can urinary PCA3 Supplement PSA in the early detection of prostate cancer?. In: Journal of Clinical Oncology. 2014 ; Vol. 32, No. 36. pp. 4066-4072.
@article{428cb5b0e2d4471b8292007bc33fbb67,
title = "Can urinary PCA3 Supplement PSA in the early detection of prostate cancer?",
abstract = "Purpose: Given the limited sensitivity and specificity of prostate-specific antigen (PSA), its widespread use as a screening tool has raised concerns for the overdiagnosis of low-risk and the underdiagnosis of high-grade prostate cancer. To improve early-detection biopsy decisions, the National Cancer Institute conducted a prospective validation trial to assess the diagnostic performance of the prostate cancer antigen 3 (PCA3) urinary assay for the detection of prostate cancer among men screened with PSA. Patients and Methods: In all, 859 men (mean age, 62 years) from 11 centers scheduled for a diagnostic prostate biopsy between December 2009 and June 2011 were enrolled. The primary outcomes were to assess whether PCA3 could improve the positive predictive value (PPV) for an initial biopsy (at a score >60) and the negative predictive value (NPV) for a repeat biopsy (at a score <20). Results: For the detection of any cancer, PPV was 80{\%} (95{\%} CI, 72{\%} to 86{\%}) in the initial biopsy group, and NPV was 88{\%} (95{\%} CI, 81{\%} to 93{\%}) in the repeat biopsy group. The addition of PCA3 to individual risk estimation models (which included age, race/ethnicity, prior biopsy, PSA, and digital rectal examination) improved the stratification of cancer and of high-grade cancer. Conclusion: These data independently support the role of PCA3 in reducing the burden of prostate biopsies among men undergoing a repeat prostate biopsy. For biopsy-naive patients, a high PCA3 score (>60) significantly increases the probability that an initial prostate biopsy will identify cancer.",
author = "Wei, {John T.} and Ziding Feng and Partin, {Alan W.} and Elissa Brown and Ian Thompson and Lori Sokoll and Chan, {Daniel W.} and Yair Lotan and Kibel, {Adam S.} and Busby, {J. Erik} and Mohamed Bidair and Lin, {Daniel W.} and Taneja, {Samir S.} and Rosalia Viterbo and Joon, {Aron Y.} and Jackie Dahlgren and Jacob Kagan and Sudhir Srivastava and Sanda, {Martin G.}",
year = "2014",
month = "12",
day = "20",
doi = "10.1200/JCO.2013.52.8505",
language = "English (US)",
volume = "32",
pages = "4066--4072",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "36",

}

TY - JOUR

T1 - Can urinary PCA3 Supplement PSA in the early detection of prostate cancer?

AU - Wei, John T.

AU - Feng, Ziding

AU - Partin, Alan W.

AU - Brown, Elissa

AU - Thompson, Ian

AU - Sokoll, Lori

AU - Chan, Daniel W.

AU - Lotan, Yair

AU - Kibel, Adam S.

AU - Busby, J. Erik

AU - Bidair, Mohamed

AU - Lin, Daniel W.

AU - Taneja, Samir S.

AU - Viterbo, Rosalia

AU - Joon, Aron Y.

AU - Dahlgren, Jackie

AU - Kagan, Jacob

AU - Srivastava, Sudhir

AU - Sanda, Martin G.

PY - 2014/12/20

Y1 - 2014/12/20

N2 - Purpose: Given the limited sensitivity and specificity of prostate-specific antigen (PSA), its widespread use as a screening tool has raised concerns for the overdiagnosis of low-risk and the underdiagnosis of high-grade prostate cancer. To improve early-detection biopsy decisions, the National Cancer Institute conducted a prospective validation trial to assess the diagnostic performance of the prostate cancer antigen 3 (PCA3) urinary assay for the detection of prostate cancer among men screened with PSA. Patients and Methods: In all, 859 men (mean age, 62 years) from 11 centers scheduled for a diagnostic prostate biopsy between December 2009 and June 2011 were enrolled. The primary outcomes were to assess whether PCA3 could improve the positive predictive value (PPV) for an initial biopsy (at a score >60) and the negative predictive value (NPV) for a repeat biopsy (at a score <20). Results: For the detection of any cancer, PPV was 80% (95% CI, 72% to 86%) in the initial biopsy group, and NPV was 88% (95% CI, 81% to 93%) in the repeat biopsy group. The addition of PCA3 to individual risk estimation models (which included age, race/ethnicity, prior biopsy, PSA, and digital rectal examination) improved the stratification of cancer and of high-grade cancer. Conclusion: These data independently support the role of PCA3 in reducing the burden of prostate biopsies among men undergoing a repeat prostate biopsy. For biopsy-naive patients, a high PCA3 score (>60) significantly increases the probability that an initial prostate biopsy will identify cancer.

AB - Purpose: Given the limited sensitivity and specificity of prostate-specific antigen (PSA), its widespread use as a screening tool has raised concerns for the overdiagnosis of low-risk and the underdiagnosis of high-grade prostate cancer. To improve early-detection biopsy decisions, the National Cancer Institute conducted a prospective validation trial to assess the diagnostic performance of the prostate cancer antigen 3 (PCA3) urinary assay for the detection of prostate cancer among men screened with PSA. Patients and Methods: In all, 859 men (mean age, 62 years) from 11 centers scheduled for a diagnostic prostate biopsy between December 2009 and June 2011 were enrolled. The primary outcomes were to assess whether PCA3 could improve the positive predictive value (PPV) for an initial biopsy (at a score >60) and the negative predictive value (NPV) for a repeat biopsy (at a score <20). Results: For the detection of any cancer, PPV was 80% (95% CI, 72% to 86%) in the initial biopsy group, and NPV was 88% (95% CI, 81% to 93%) in the repeat biopsy group. The addition of PCA3 to individual risk estimation models (which included age, race/ethnicity, prior biopsy, PSA, and digital rectal examination) improved the stratification of cancer and of high-grade cancer. Conclusion: These data independently support the role of PCA3 in reducing the burden of prostate biopsies among men undergoing a repeat prostate biopsy. For biopsy-naive patients, a high PCA3 score (>60) significantly increases the probability that an initial prostate biopsy will identify cancer.

UR - http://www.scopus.com/inward/record.url?scp=84916237853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916237853&partnerID=8YFLogxK

U2 - 10.1200/JCO.2013.52.8505

DO - 10.1200/JCO.2013.52.8505

M3 - Article

VL - 32

SP - 4066

EP - 4072

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 36

ER -